Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

OPEN ACCESS

Articles

Page Path
HOME > Clin Endosc > Ahead-of print articles > Article
Original Article Outcomes of second-generation transoral incisionless fundoplication in a Mediterranean cohort: a retrospective study of the first Turkish experience with typical and extraesophageal gastroesophageal reflux disease symptoms
Fatih Aslan1orcid, Serhat Ozer1orcid, Ozgur Aktas2orcid, Sevde E. Odemis2orcid

DOI: https://doi.org/10.5946/ce.2025.462
Published online: August 13, 2026

1Department of Gastroenterology, Koç University Hospital, Istanbul, Turkey

2Koç University, Istanbul, Turkey

Correspondence: Fatih Aslan Koç University School of Medicine, 34010 Istanbul, Turkey E-mail: faslan@ku.edu.tr
• Received: December 10, 2025   • Revised: January 21, 2026   • Accepted: January 30, 2026

© 2026 Korean Society of Gastrointestinal Endoscopy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 1,109 Views
  • 123 Download
  • Background/Aims
    Transoral incisionless fundoplication (TIF 2.0) has demonstrated efficacy in Western populations; however, data from Mediterranean cohorts are limited. This prospective observational study with retrospective analysis aimed to evaluate the safety and short-term efficacy of TIF 2.0 in Turkish patients with gastroesophageal reflux disease (GERD), using culturally validated questionnaires for both typical and extraesophageal symptoms.
  • Methods
    Twenty-eight patients with chronic GERD underwent TIF 2.0 between July 2023 and March 2025 at a single Turkish tertiary center. Patient data were prospectively collected at baseline and six months after the procedure. The primary outcome was composite clinical success at 6 months, defined as improvement in at least one subjective measure (>50% improvement in gastroesophageal reflux disease health-related quality of life (GERD-HRQL) or reflux symptom index (RSI) total scores) and at least one of the following: discontinuation of proton pump inhibitor (PPI) use or endoscopic healing of esophagitis.
  • Results
    All procedures were technically successful, with no serious adverse events. Mean GERD-HRQL scores decreased significantly from 27.0±10.1 to 5.0±3.9 (p<0.001), while RSI scores decreased from 16.1±9.1 to 3.9±5.1 (p<0.001). At six months, 85.7% of the patients discontinued PPI use, with the remaining patients requiring occasional use, and patient satisfaction improved from 0% to 86% (p<0.001). All patients with baseline esophagitis (n=24) exhibited complete endoscopic healing.
  • Conclusions
    As a pilot study, these preliminary findings support TIF 2.0 as a viable treatment option and provide the foundation for future multicenter trials.
Gastroesophageal reflux disease (GERD) is a prevalent chronic disorder resulting from the retrograde movement of gastric contents into the esophagus, causing symptoms such as heartburn and regurgitation, and potential complications such as esophagitis and Barrett’s esophagus.1,2 The standard approach for GERD management begins with lifestyle modifications and the use of proton pump inhibitors (PPIs) to control stomach acid production. However, in some patients, long-term PPI use is associated with limited symptom relief or accompanied by adverse effects, rendering the condition inadequately managed.3,4 In such cases, surgical intervention is often considered to achieve durable symptom control and prevent disease progression. Traditionally, laparoscopic fundoplication—where the upper part of the stomach is wrapped around the esophagus to strengthen the lower esophageal sphincter through abdominal incisions—has been the preferred surgical option.5 Although effective in most patients, this invasive approach can lead to complications, such as postoperative pain, gas-bloat syndrome, and incisional hernias, which can significantly hinder the patient’s quality of life.6
Transoral incisionless fundoplication (TIF) is an endoscopic technique that has emerged as a minimally invasive alternative for the management of GERD. This procedure involves reshaping the gastroesophageal junction internally and creating a robust anti-reflux valve through serosa-to-serosa plications, without the need for external incisions.7 The TIF 2.0 technique, mainly the EsophyX-Z device (EndoGastric Solutions, Inc.), is a novel approach that forms a 270-degree barrier around the esophagus, strengthening the lower esophageal sphincter and minimizing common side effects such as gas-bloat syndrome seen in fundoplication.8 Therefore, TIF 2.0 provides an effective, less invasive alternative for long-term GERD management in patients seeking symptom control without continuous medication.
While the efficacy of TIF 2.0 is well-documented in American and Western European studies,8-10 data from the Mediterranean regions, particularly Turkey, are notably absent. This gap in knowledge is clinically relevant for several reasons. Firstly, an epidemiological study involving 17 cities and 3214 patients established the prevalence of GERD in the Turkish population to be 22.8% and Turkish patients exhibit specific phenotypic traits, including a regurgitation-dominant symptom profile and high rates of Helicobacter pylori infection, complicating direct extrapolation of Western data.11 Second, Mediterranean populations have distinct dietary patterns, such as a high consumption of olive oil and spicy foods, which have been proven to influence the pathophysiology of GERD and treatment response.12,13 Lastly, lifestyle factors, such as high smoking prevalence in 30.8% of adults (21.1 million current smokers as of 2024), with a higher prevalence rate among males than among females (42.1% vs. 19.7%).14 Considering the aforementioned differences, establishing efficacy in Turkish patients is essential to inform clinical practice guidelines and healthcare reimbursement decisions regarding TIF 2.0.
Considering the promising outcomes associated with TIF 2.0,9,15 our study represents the first Turkish experience with TIF 2.0, uniquely employing validated Turkish versions of both the GERD-HRQL for typical symptoms and the reflux symptom index (RSI) for atypical manifestations. By prospectively collecting comprehensive symptom data in a real-world clinical setting, we aimed to evaluate whether TIF 2.0 can achieve comparable efficacy and safety outcomes in a Mediterranean population while addressing the full spectrum of GERD symptomatology.
Study design and patient selection
Twenty-eight patients were enrolled in the present study after meeting the predetermined inclusion and exclusion criteria, with the operations being conducted between July 2023 and March 2025. Data for the cohort were collected prospectively using a standardized protocol at predefined time points (baseline and 6 months post-procedure), but the analysis was conducted retrospectively. All procedures were performed by two advanced endoscopists (F.A. and S.O.).
Before the procedure, all patients underwent esophagogastroduodenoscopy to assess the grading of esophagitis, if present, and the Hill classification of the gastroesophageal flap valve. For patients with confirmed esophagitis, further pH testing was not conducted; however, in patients without esophagitis 48-hour (2-day) Bravo pH testing was conducted after a 7-day PPI washout to confirm the presence of chronic GERD.
As an initial feasibility study evaluating TIF 2.0 in a Turkish Population, no formal power analysis was conducted, which is consistent with the CONSORT guidelines for pilot trials. The sample size of 28 patients was determined based on (1) consecutive eligible patients during the study period, (2) adequate precision for estimating technical success rates and safety profiles with 95% confidence intervals (CIs), (3) comparability to published single-center TIF experiences (20–40 patients), and (4) practical considerations regarding procedure availability. Given the small sample size, the results should be interpreted with caution, and point estimates should be considered preliminary. These findings are intended to inform the design of future adequately powered multicenter trials in Mediterranean populations.
Selection criteria and pre-procedure assessment
The inclusion criteria consisted of adult patients aged 18–80 years with a history of GERD lasting more than one year. Eligible patients had a history of daily PPI use for over six months; however, they still experienced troublesome atypical symptoms and/or regurgitation (with or without heartburn) during medical treatment. To be included, the patients needed to provide signed informed consent, be willing to undergo pH testing, and answer the validated Turkish versions of the GERD-HRQL and RSI questionnaires at baseline and 6 months.
The exclusion criteria for the study included body mass index (BMI) greater than 35 kg/m2, esophagitis grade D, Hill Grade greater than 2, hiatal hernia >2 cm, Barrett’s esophagus >2 cm, previous esophageal or gastric ulcer, fixed esophageal stricture or narrowing, portal hypertension, and/or varices. Patients with gastric outlet obstruction, stenosis, gastroparesis, or coagulation disorders were excluded. Other criteria excluded patients with a history of any resective gastric or esophageal surgery, those previously undergoing anti-reflux surgery deemed unsuitable for TIF based on the physician’s judgment, and those with Zenker's diverticulum, esophageal epiphrenic diverticulum, scleroderma, achalasia, dermatomyositis, eosinophilic esophagitis, or cirrhosis. Pregnant women, those planning a pregnancy within 12 months of treatment, and patients enrolled in other device or drug studies that might have confounded the results were excluded.
All patients underwent a comprehensive pre-procedure evaluation, including upper gastrointestinal endoscopy with assessment of esophagitis and Hill grade, and ambulatory pH monitoring. 24-hour pH monitoring was performed in 16 patients (57%), while 48-hour wireless pH monitoring was performed in 12 patients (43%). Lyon Consensus 2.0 criteria were applied for GERD diagnosis in patients without esophagitis or with Los Angeles (LA) grade A; acid exposure time (AET) >6% was considered conclusive evidence of pathological reflux on 48-hour wireless pH monitoring after a 7-day PPI washout. For patients with LA grade B or higher, a 24-hour pH test off PPIs was deemed sufficient, and AET >6% was also considered to be pathological reflux.16
GERD assessment via questionnaires
All patients completed the validated Turkish versions of the two standardized questionnaires. During the first assessment, all demographic characteristics of the patients, including the duration of GERD and other parameters, were collected. During both the first and second meetings with the patients, Turkish validated versions17,18 of the GERD-HRQL for the assessment of typical GERD symptoms and the RSI for the assessment of atypical symptoms were administered to each patient. Questionnaire-based assessments were conducted by S.O. and O.A. research conductors who were not involved in TIF 2.0 procedures.
The GERD-HRQL is composed of ten pillars: six of them assess heartburn, two are related to dysphagia, one is related to bloating, and the last is related to the impact of medications on daily life, with a maximum total score of 50.19 The last part of the GERD-HRQL scale also contains a satisfactory assessment that asks patients about their satisfaction level with their current health status. The components of the GERD-HRQL are assessed using a scale that ranges from 0 (no symptoms) to 5 (worst symptoms); the higher the score, the more severe the typical GERD symptoms. The RSI, on the other hand, is composed of nine items that evaluate atypical GERD symptoms, such as cough, hoarseness, throat clearing, dysphagia, and excess mucus clearing, with a maximum total score of 45, with an RSI >13 considered abnormal.20
Outcome measures
The primary outcome was composite clinical success at six months, defined as improvement in at least one subjective measure (>50% reduction in the GERD-HRQL or RSI total scores from baseline and at least one of the following: (1) complete discontinuation of daily PPI use or (2) healing of esophagitis (resolution of erosive disease and improvement in LA grading). Secondary outcomes included individual GERD-HRQL and RSI domain scores, PPI use status, esophagitis healing rate, patient satisfaction, and adverse events.
TIF 2.0 procedure
All procedures were performed by two experienced endoscopists (F.A. and S.O.), and the procedures were conducted according to the latest protocols and guidelines of the EsophyX device.21 Under general anesthesia and endotracheal intubation, the EsophyX device was advanced transorally over a flexible endoscope for continuous visualization. Using a helical retractor positioned just below the Z-line, the fundus of the stomach was folded around the lower esophagus using tissue-manipulating tools. Once secured, the gastroesophageal junction was separated from the diaphragm, and “H” fasteners were applied. This process was repeated in three additional positions to achieve partial fundoplication. Patients were typically discharged within 48 hours and advised to follow standard dietary and activity restrictions. In addition to patient inquiries, all patients were asked to visit our clinic 1 and 6 months postoperatively. Patients will continue to visit annually for 5 years for routine control purposes.
Statistical analysis
All statistical analyses were conducted using the STATA software (SE.18.5). Descriptive baseline characteristics were also calculated. Comparative analyses of mean and total questionnaire score changes at 6 months follow-up compared to the baseline were calculated using paired t-tests and the Mann-Whitney U-test, as appropriate. McNemar’s and Bowker’s tests of symmetry were used to compare the categorical analyses of patient satisfaction.
The primary effectiveness endpoint of the study was composite clinical success at six months, defined as improvement in at least one subjective (>50% reduction in GERD-HRQL or RSI scores, or patient satisfaction transition from dissatisfaction to satisfaction) and one objective (endoscopic healing of esophagitis or discontinuation of daily PPI use). Two-sided p<0.05 were considered to be statistically significant. Given the pilot design and limited sample size, multivariate regression for the predictors of success was not performed to avoid overfitting. Instead, descriptive statistics with 95% CIs were provided for all primary outcomes.
Ethical considerations
The approval of the research was granted by the Koç University Institutional Ethical Review Board (no. 2024.382. IRB2.164), and the study adhered to the principles of the Declaration of Helsinki. All patients provided written informed consent prior to the initiation of the retrospective study.
Patient demographic characteristics
Between July 2023 and March 2025, 28 patients underwent TIF 2.0 procedures and were followed up for 6 months. There were 24 male and 4 female patients. The mean age was 46.9±10.4 years, the median BMI was 26.2 kg/m2 with a range of 23.7 to 31. The median GERD duration was 10 years (1–20), and the median PPI or anti-acid usage was 10 (1–20) years. No patients reported excessive alcohol consumption. Social drinking22 was observed in eight patients (28.6%). Twenty patients (71.4%) reported smoking.
Twenty-four patients (85.7%) presented with endoscopic esophagitis: LA grade A (n=8, 28.6%), grade B (n=14, 50.0%), or grade C (n=2, 7.1%). All patients were receiving PPIs or anti-acid medications at admission/baseline. The detailed demographic characteristics of the patients are shown in Table 1.
TIF 2.0 outcomes and safety
All 28 procedures were technically successful in creating the target valve configuration. The median procedure duration was 45 (range, 19–95) minutes, and the median hospitalization duration was 2 (range, 1–3) days. The median number of fasteners used was 20 (interquartile range, 20–21.5). Minor superficial mucosal injuries at the fastener deployment sites were observed in 25 patients (89%). These represent expected, self-limited findings inherent to the TIF 2.0 technique and are not considered adverse events. Minor adverse events occurred in three patients (10.7%): self-limited upper gastrointestinal bleeding within 24 hours managed endoscopically with hemostatic forceps (Coagrasper; Olympus). All superficial injuries healed spontaneously without intervention, as confirmed by a six-month follow-up endoscopy. No perforations, pneumothorax, or procedure-related mortalities were observed. Notably, none of the patients developed dysphagia or gas-bloating syndrome during follow-up. No reinterventions or conversions to laparoscopic fundoplication were required.
Patient-reported symptomatic outcomes
At six months, 26 patients (92.9%) achieved the primary composite endpoint of clinical success. The total GERD-HRQL scores prior to the TIF 2.0 procedure and 6 months follow-up improved significantly, evident from the mean difference of 21.96 with a range of 17.78 to 26.15 (p<0.001). The mean total GERD-HRQL score was 26.81 pre-operatively which improved to 5.04 postoperatively, highlighting the improvement in typical GERD symptoms. Similarly, the total RSI scores showed a significant reduction, with a mean difference of 12.18 (95% CI, 8.47–15.89) (p<0.001). Both typical GERD and extraesophageal symptoms improved notably after TIF. The total mean scores of both questionnaires are shown in Table 2, and the mean scores for each component of the GERD-HRQL and RSI questionnaires are shown in Tables 3 and 4, respectively. For enhanced visual representation, the mean scores for each question are shown in Figure 1 for the GERD-HRQL and Figure 2 for the RSI questionnaires.
As part of the GERD-HRQL questionnaire, satisfaction with current health status was examined; at baseline, 96% (n=27) of patients were dissatisfied and 4% (n=1) were neutral with their health status prior to the TIF procedure. At six-months follow-up questionnaire, 86% (n=24) of the patients were satisfied, 7% (n=2) were neutral, and 7% (n=2) remained dissatisfied. This represented a marked shift in the satisfaction distribution, with the majority of patients transitioning from a state of dissatisfaction to satisfaction, which was statistically significant (p<0.001). Two patients who accounted for the dissatisfied patient population post-operation period continued to use PPIs, albeit at a dose much lower than before the operation; once or twice per month usage was reported, and their total questionnaire scores still showed score improvements postoperatively. The satisfaction assessment is illustrated in Figure 3. Lastly, during the 6-month follow-up, endoscopic examination revealed elimination of esophagitis in all 18 patients. Macroscopic healing of the lesion is shown in Figure 4.
Subgroup analysis
Patients with predominantly atypical symptoms (baseline RSI >20, n=8) showed clinical success rates (87.5%) similar to those with typical symptom predominance (94.4%, p=0.54). No significant differences in outcomes were observed based on age, BMI, baseline endoscopic esophagitis, or duration of GERD.
This study provides the first insights into the efficacy of TIF 2.0 in the elimination of typical and atypical symptoms of GERD in a Turkish population. Our results are particularly notable for demonstrating improvements in GERD symptoms using culturally validated assessment tools and addressing a critical gap in the international TIF literature regarding the efficacy of TIF across diverse geographic populations.
Improvement in the quality of life and esophagitis healing are considered the primary goals in GERD management and have been referred to as endpoints in GERD-related studies.23 In alignment with these goals, the outcomes of our study are comparable with those of several retrospective and prospective studies on patients with extraesophageal and typical GERD symptoms. Stefanidis et al.24 reported that 72.7% of patients achieved complete elimination of typical GERD symptoms without PPI usage after TIF, with 13.6% reporting improved symptoms with occasional PPI use and 13.6% reporting no improvement in their daily symptoms and reliance on daily PPI usage. It is important to note that none of the patients in our study were subjected to daily PPI use after the TIF procedure; however, a reduced dosage and duration were noted. With its randomized clinical trial design, the TEMPO trial showed that TIF 2.0 eliminated troublesome regurgitation in 97% of patients compared to only 50% in the PPI group, and 62% of TIF patients had improvements in their extraesophageal symptoms, assessed with the same validated RSI questionnaire,10 highlighting TIF’s role in eliminating atypical symptoms of GERD. Notably, a recent multicenter study with 81 patients on TIF 2.0 displayed similar results: the GERD-HRQL score improved by 89%, the RSI score improved in 85% of patients compared to baseline scores, patient satisfaction improved from 8% to 79%, and no serious adverse events were noted.25
TIF is the preferred treatment modality for patients with chronic GERD. Our study revealed no significant adverse events such as perforation or other causes that led to extended hospitalization. However, mild esophageal mucosal injury and fastener-related gastrointestinal bleeding were observed in 25 (89%) and three (10%) patients, respectively. Traditional fundoplication surgery is heavily associated with postsurgical complications such as bloating, dysphagia, and gas-bloat syndrome,6 all patients in our study were exempt from these adverse findings. Post-fundoplication adverse events were clearly identified in the LOTUS trial, in which the highly competent gastroesophageal valve demonstrated higher complication rates than medication-based treatments, even in a significant percentage of the population at the 5-year follow-up.26 As mentioned above, our study revealed no adverse events typically experienced in conventional fundoplication surgery.
However, the literature contains studies that have shed light on the long-term effectiveness of TIF in terms of their safety profile. Repici et al.27 reported worsened distal esophageal acid exposure in 66.7% of patients 12 months after the TIF procedure albeit the single-center nature of the study might have introduced bias into these adverse event outcomes. Hoppo et al.28 first reported a 68% non-responder rate, and out of 19 patients, 10 had been converted to laparoscopic fundoplication due to recurrent GERD symptoms and Witteman et al.29 similarly reported that 37% of patients required revision surgery within three years after TIF procedure. Stefanidis et al.24 also reported the occurrence of pneumothorax in one patient who was treated successfully, but was excluded from the analysis and lost to follow-up. These outcomes indicate variability in long-term TIF outcomes, especially in patients with more severe GERD or those with no or minimal preoperative response to high-dose PPIs. It must also be noted that the techniques have improved since the publication of these studies, and our outcomes revealed symptom improvement at 6 months, with no reports of worsened symptoms or revision needs. With these adverse events noted, TIF may be more effective in carefully selected patients with well-defined indications, especially when esophagitis is not severe.
Our study echoes the extraesophageal symptom improvement findings of Haseeb et al.’s30 meta-analysis, in which TIF caused a significant reduction in RSI scores, with more than two-thirds of the patients satisfied with their postoperative health status and three-fourths off PPIs. Our findings align with the meta-analysis, and this is likely due to our strict inclusion criteria: judiciously selected patients increased the likelihood of success of the TIF 2.0.
While TIF 2.0 outcomes have been extensively reported in Western cohorts, our study represents the first comprehensive evaluation in a Mediterranean population. Critical demographic differences distinguished our cohort from those of previous studies. The smoking rate in our population is substantially higher (71.4%) than that reported in Western TIF series, where smoking prevalence was 34%.29 In addition, 28.6% reported alcohol consumption as a social drinker, contrasting sharply with Western studies, where alcohol use is frequently documented. Our cohort had a notably higher proportion of male patients (86%) than the landmark Western series, such as the TEMPO trial, in which males constituted 45% of the study population,15 which may reflect referral patterns and cultural factors influencing healthcare-seeking behaviors in Turkey; however, as a pilot trial, a larger patient population is required to prove this postulation. These lifestyle patterns, together with regional and metabolic differences, may influence GERD pathophysiology via different mechanisms, including the modulation of inflammatory responses and alterations in gastric and esophageal motility.13 Despite these notable demographic differences, our outcomes are comparable, if not superior, to those reported in the literature, supporting the broader applicability of TIF 2.0, across diverse populations.
Our study has several limitations. First, the small sample size of 28 patients limits the generalizability of our findings, although significant improvements have been demonstrated. As an exploratory pilot study with a small sample size, our results should be interpreted with caution and considered preliminary. This single-center design may have caused institutional biases and restricted the applicability of our findings to other healthcare institutions. Second, the short follow-up period, which is limited to 6 months, prevents truly capturing the long-term efficacy and safety of the TIF 2.0 procedure. Although efforts were made to ensure data integrity, the prospectively collected but retrospectively analyzed nature of the study could introduce additional biases such as selection bias. Another notable limitation was the lack of control pH monitoring at the 6-month follow-up. Lastly, one must consider the possibility of subjective bias, as the study relied on questionnaire-based symptom assessments, even though they were validated and assessed by research assistants who were not involved in the procedure.
Considering the current literature, the TIF 2.0 procedure should be further tested in specific patient subgroups, such as those with more severe esophagitis, allowing the guidelines to narrow and refine patient selection criteria. Future studies using pH impedance monitoring should enhance the quality of the findings for future outcome evaluations.
In conclusion, the first Turkish experience demonstrated that TIF 2.0 achieves excellent clinical outcomes comparable to international benchmarks, highlights significant improvements in both typical and extraesophageal symptoms along with a positive shift in patient satisfaction at postoperative follow-up. In addition to symptomatic relief, the resolution of esophagitis renders TIF 2.0 a valuable and safe alternative for GERD management. These results validate the efficacy of TIF across diverse geographical populations and support its integration into treatment algorithms for appropriately selected patients with GERD in Mediterranean healthcare settings. TIF 2.0 offers a minimally invasive alternative to long-term PPI therapy and conventional fundoplication surgery for the management of chronic GERD without the fear of post-fundoplication syndromes.
Fig. 1.
Mean changes in gastroesophageal reflux disease health-related quality of life (GERD-HRQL) questionnaire before transoral incisionless fundoplication (TIF) procedure and after 6 months follow-up period.
ce-2025-462f1.jpg
Fig. 2.
Mean changes in reflux symptom index (RSI) questionnaire before transoral incisionless fundoplication (TIF) procedure and after 6 months follow-up period.
ce-2025-462f2.jpg
Fig. 3.
Satisfaction with current health status comparison of the patients before and 6 months after the transoral incisionless fundoplication (TIF) procedure, investigated using gastroesophageal reflux disease health-related quality of life (GERD-HRQL) questionnaire.
ce-2025-462f3.jpg
Fig. 4.
Comparative endoscopic evaluation of endoscopic images demonstrating macroscopic healing of esophagitis before and 6 months after the transoral incisionless fundoplication (TIF) procedure. (A) Endoscopic image during the TIF procedure. (B) Endoscopic image before the TIF procedure. (C) Endoscopic image right after the TIF procedure, encompassing the precise usage of the EsophyX device. (D) Endoscopic image 6 months after the TIF procedure.
ce-2025-462f4.jpg
ce-2025-462f5.jpg
Table 1.
Patient demographic characteristics
Characteristic Value
No. of patients 28 (100.0)
Sex (male/female) 24 (85.7)/4 (14.3)
Age (yr) 46.85±10.35
BMI (kg/m2) 26.2 (23.7–31)
GERD duration (yr) 10 (1–20)
PPI or anti-acid usage (yr) 10 (1–20)
Social drinkera) 8 (28.6)
Smokers 20 (71.4)
Esophagitis (no. of patients) 24 (85.7)
 No esophagitis 4 (14.3)
 Grade A esophagitis 8 (28.6)
 Grade B esophagitis 14 (50.0)
 Grade C esophagitis 2 (7.1)
Hiatal (Hill) grade (no. of patients) 23 (82.1)
 1 2 (7.1)
 2 22 (78.6)
PPI or anti-acid usage at entry
 Lansoprazole 8 (28.6)
 Esomeprazole 12 (42.9)
 Pantoprazole 3 (10.7)
 Alginic acid 4 (14.3)
 Famotidine 1 (3.6)

Values are presented as mean±standard deviation, median (range), or number (%).

BMI, body mass index, GERD, gastroesophageal reflux disease; PPI, proton pump inhibitor.

a)p-values were calculated using the paired t-test.

Table 2.
Changes in mean symptom scores from pre-TIF procedure to 6-month follow-up
Questionnaires Mean total pre-TIF score Mean total post-TIF score Difference in means (95% CI) p-valuea)
GERD-HRQL score 27±10.07 5.04±3.92 21.96 (17.78–26.15) <0.001
RSI 16.11±9.09 3.93±5.1 12.18 (8.47–15.89) <0.001

Values are presented as mean±standard deviation unless otherwise indicated.

TIF, transoral incisionless fundoplication; CI, confidence interval; GERD-HRQL, gastroesophageal reflux disease health-related quality of life; RSI, reflux symptom index.

a)p-values are calculated using the paired t-test.

Table 3.
Changes in mean scores of each question based in GERD-HRQL questionnaire before TIF procedure and after 6 months of treatment
GERD-HRQL questions Pre-TIF Post-TIF 6 months p-value
How bad is your heartburn? 3.86 0.61 <0.001
Heartburn when lying down? 3.5 0.89 <0.001
Heartburn when standing up? 2.71 0.43 <0.001
Heartburn after meals? 3.57 0.46 <0.001
Does heartburn change your diet? 2.36 0.75 <0.001
Does heartburn wake you from sleep? 3.07 0.21 <0.001
Do you have difficulty swallowing? 0.86 0.14 0.0022
Do you have pain with swallowing? 0.71 0.07 0.0034
Do you have bloating or gassy feelings? 2.93 1.25 <0.001
If you take medication, does this affect your daily life? 3.43 0.21 <0.001

GERD-HRQL, gastroesophageal reflux disease health-related quality of life; TIF, transoral incisionless fundoplication.

Table 4.
Changes in mean scores of each question based in RSI questionnaire before TIF procedure and after 6 months of treatment
RSI questions Pre-TIF Post-TIF 6 mo p-value
Hoarseness or a problem with your voice. 1.11 0.32 0.0045
Clearing your throat. 2.39 0.96 <0.001
Excess throat mucus or postnasal drip. 2 0.71 <0.001
Difficulty swallowing food, liquids, or pills. 0.64 0.11 0.0112
Coughing after you ate or after lying down. 1.54 0.32 <0.001
Breathing difficulties or choking episodes. 0.86 0.04 0.004
Troublesome or annoying cough. 1.61 0.29 <0.001
Sensations of something sticking in your throat or a lump in your throat. 1.79 0.36 <0.001
Heartburn, chest pain, indigestion, or stomach acid coming up. 4.18 0.82 <0.001

RSI, reflux symptom index; TIF, transoral incisionless fundoplication.

  • 1. Yamasaki T, Hemond C, Eisa M, et al. The changing epidemiology of gastroesophageal reflux disease: are patients getting younger? J Neurogastroenterol Motil 2018;24:559–569.
  • 2. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900–1920.ArticlePubMedPMC
  • 3. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2022;117:27–56.ArticlePubMed
  • 4. Heidelbaugh JJ, Nostrant TT, Kim C, et al. Management of gastroesophageal reflux disease. Am Fam Physician 2003;68:1311–1318.ArticlePMC
  • 5. Seeras K, Bittar K, Siccardi MA. Nissen fundoplication. StatPearls Publishing; 2026.
  • 6. Sobrino-Cossío S, Soto-Pérez JC, Coss-Adame E, et al. Post-fundoplication symptoms and complications: diagnostic approach and treatment. Rev Gastroenterol Mex 2017;82:234–247.
  • 7. Testoni PA, Mazzoleni G, Testoni SG. Transoral incisionless fundoplication for gastro-esophageal reflux disease: techniques and outcomes. World J Gastrointest Pharmacol Ther 2016;7:179–189.ArticlePubMed
  • 8. Testoni PA, Testoni S, Distefano G, et al. Transoral incisionless fundoplication with EsophyX for gastroesophageal reflux disease: clinical efficacy is maintained up to 10 years. Endosc Int Open 2019;7:E647–E654.ArticlePubMedPMC
  • 9. Bell RC, Freeman K, Heidrick R, et al. Transoral incisionless fundoplication demonstrates durability at up to 9 years. Therap Adv Gastroenterol 2021;14:17562848211004827.ArticlePubMedPMC
  • 10. Trad KS, Barnes WE, Simoni G, et al. Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial. Surg Innov 2015;22:26–40.ArticlePMCPDF
  • 11. Bor S, Kitapcioglu G, Kasap E. Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori. World J Gastroenterol 2017;23:525–532.ArticlePubMedPDF
  • 12. Herdiana Y. Functional food in relation to gastroesophageal reflux disease (GERD). Nutrients 2023;15:3583.ArticlePubMedPMC
  • 13. Newberry C, Lynch K. The role of diet in the development and management of gastroesophageal reflux disease: why we feel the burn. J Thorac Dis 2019;11:S1594–S1601.ArticlePubMedPMC
  • 14. World Health Organization (WHO). WHO global report on trends in prevalence of tobacco use 2000-2024 and projections 2025-2030. WHO; 2025.ArticlePubMedPMC
  • 15. Trad KS, Barnes WE, Prevou ER, et al. The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) is safe, durable, and cost-effective. Surg Innov 2018;25:149–157.
  • 16. Gyawali CP, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut 2024;73:361–371.ArticlePubMedPMCPDF
  • 17. Akbulut S, Aydinli FE, Kuşçu O, et al. Reliability and validity of the turkish reflux symptom index. J Voice 2020;34:e23–e965.ArticlePubMedPMC
  • 18. Trabzon Ş, Sert H. Validity and reliability of the turkish version of the gastroesophageal reflux disease quality of life questionnaire. Clin Exp Med Sci 2024;14:95–101.Article
  • 19. Velanovich V, Vallance SR, Gusz JR, et al. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg 1996;183:217–224.Article
  • 20. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice 2002;16:274–277.PubMed
  • 21. Bell RC, Cadière GB. Transoral rotational esophagogastric fundoplication: technical, anatomical, and safety considerations. Surg Endosc 2011;25:2387–2399.ArticlePubMed
  • 22. Centers for Disease Control and Prevention (CDC). Moderate alcohol use [Internet]. CDC; 2025 [cited 2025 Feb 25]. Available from: https://www.cdc.gov/alcohol/about-alcohol-use/moderate-alcohol-use.html ArticlePubMed
  • 23. Bell RC, Mavrelis PG, Barnes WE, et al. A prospective multicenter registry of patients with chronic gastroesophageal reflux disease receiving transoral incisionless fundoplication. J Am Coll Surg 2012;215:794–809.
  • 24. Stefanidis G, Viazis N, Kotsikoros N, et al. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy. Dis Esophagus 2017;30:1–8.ArticlePubMed
  • 25. Canto MI, Diehl DL, Parker B, et al. Outcomes of transoral incisionless fundoplication (TIF 2.0): a prospective multicenter cohort study in academic and community gastroenterology and surgery practices (with video). Gastrointest Endosc 2025;101:90–102.ArticlePDF
  • 26. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011;305:1969–1977.ArticlePubMed
  • 27. Repici A, Fumagalli U, Malesci A, et al. Endoluminal fundoplication (ELF) for GERD using EsophyX: a 12-month follow-up in a single-center experience. J Gastrointest Surg 2010;14:1–6.ArticlePubMed
  • 28. Hoppo T, Immanuel A, Schuchert M, et al. Transoral incisionless fundoplication 2.0 procedure using EsophyX™ for gastroesophageal reflux disease. J Gastrointest Surg 2010;14:1895–1901.ArticlePubMedPDF
  • 29. Witteman BP, Strijkers R, de Vries E, et al. Transoral incisionless fundoplication for treatment of gastroesophageal reflux disease in clinical practice. Surg Endosc 2012;26:3307–3315.ArticlePubMedPDF
  • 30. Haseeb M, Brown JRG, Hayat U, et al. Impact of second-generation transoral incisionless fundoplication on atypical GERD symptoms: a systematic review and meta-analysis. Gastrointest Endosc 2023;97:394–406.ArticlePubMedPMC

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Outcomes of second-generation transoral incisionless fundoplication in a Mediterranean cohort: a retrospective study of the first Turkish experience with typical and extraesophageal gastroesophageal reflux disease symptoms
        Close
      • XML DownloadXML Download
      Figure
      • 0
      • 1
      • 2
      • 3
      • 4
      Outcomes of second-generation transoral incisionless fundoplication in a Mediterranean cohort: a retrospective study of the first Turkish experience with typical and extraesophageal gastroesophageal reflux disease symptoms
      Image Image Image Image Image
      Fig. 1. Mean changes in gastroesophageal reflux disease health-related quality of life (GERD-HRQL) questionnaire before transoral incisionless fundoplication (TIF) procedure and after 6 months follow-up period.
      Fig. 2. Mean changes in reflux symptom index (RSI) questionnaire before transoral incisionless fundoplication (TIF) procedure and after 6 months follow-up period.
      Fig. 3. Satisfaction with current health status comparison of the patients before and 6 months after the transoral incisionless fundoplication (TIF) procedure, investigated using gastroesophageal reflux disease health-related quality of life (GERD-HRQL) questionnaire.
      Fig. 4. Comparative endoscopic evaluation of endoscopic images demonstrating macroscopic healing of esophagitis before and 6 months after the transoral incisionless fundoplication (TIF) procedure. (A) Endoscopic image during the TIF procedure. (B) Endoscopic image before the TIF procedure. (C) Endoscopic image right after the TIF procedure, encompassing the precise usage of the EsophyX device. (D) Endoscopic image 6 months after the TIF procedure.
      Graphical abstract
      Outcomes of second-generation transoral incisionless fundoplication in a Mediterranean cohort: a retrospective study of the first Turkish experience with typical and extraesophageal gastroesophageal reflux disease symptoms
      Characteristic Value
      No. of patients 28 (100.0)
      Sex (male/female) 24 (85.7)/4 (14.3)
      Age (yr) 46.85±10.35
      BMI (kg/m2) 26.2 (23.7–31)
      GERD duration (yr) 10 (1–20)
      PPI or anti-acid usage (yr) 10 (1–20)
      Social drinkera) 8 (28.6)
      Smokers 20 (71.4)
      Esophagitis (no. of patients) 24 (85.7)
       No esophagitis 4 (14.3)
       Grade A esophagitis 8 (28.6)
       Grade B esophagitis 14 (50.0)
       Grade C esophagitis 2 (7.1)
      Hiatal (Hill) grade (no. of patients) 23 (82.1)
       1 2 (7.1)
       2 22 (78.6)
      PPI or anti-acid usage at entry
       Lansoprazole 8 (28.6)
       Esomeprazole 12 (42.9)
       Pantoprazole 3 (10.7)
       Alginic acid 4 (14.3)
       Famotidine 1 (3.6)
      Questionnaires Mean total pre-TIF score Mean total post-TIF score Difference in means (95% CI) p-valuea)
      GERD-HRQL score 27±10.07 5.04±3.92 21.96 (17.78–26.15) <0.001
      RSI 16.11±9.09 3.93±5.1 12.18 (8.47–15.89) <0.001
      GERD-HRQL questions Pre-TIF Post-TIF 6 months p-value
      How bad is your heartburn? 3.86 0.61 <0.001
      Heartburn when lying down? 3.5 0.89 <0.001
      Heartburn when standing up? 2.71 0.43 <0.001
      Heartburn after meals? 3.57 0.46 <0.001
      Does heartburn change your diet? 2.36 0.75 <0.001
      Does heartburn wake you from sleep? 3.07 0.21 <0.001
      Do you have difficulty swallowing? 0.86 0.14 0.0022
      Do you have pain with swallowing? 0.71 0.07 0.0034
      Do you have bloating or gassy feelings? 2.93 1.25 <0.001
      If you take medication, does this affect your daily life? 3.43 0.21 <0.001
      RSI questions Pre-TIF Post-TIF 6 mo p-value
      Hoarseness or a problem with your voice. 1.11 0.32 0.0045
      Clearing your throat. 2.39 0.96 <0.001
      Excess throat mucus or postnasal drip. 2 0.71 <0.001
      Difficulty swallowing food, liquids, or pills. 0.64 0.11 0.0112
      Coughing after you ate or after lying down. 1.54 0.32 <0.001
      Breathing difficulties or choking episodes. 0.86 0.04 0.004
      Troublesome or annoying cough. 1.61 0.29 <0.001
      Sensations of something sticking in your throat or a lump in your throat. 1.79 0.36 <0.001
      Heartburn, chest pain, indigestion, or stomach acid coming up. 4.18 0.82 <0.001
      Table 1. Patient demographic characteristics

      Values are presented as mean±standard deviation, median (range), or number (%).

      BMI, body mass index, GERD, gastroesophageal reflux disease; PPI, proton pump inhibitor.

      a)p-values were calculated using the paired t-test.

      Table 2. Changes in mean symptom scores from pre-TIF procedure to 6-month follow-up

      Values are presented as mean±standard deviation unless otherwise indicated.

      TIF, transoral incisionless fundoplication; CI, confidence interval; GERD-HRQL, gastroesophageal reflux disease health-related quality of life; RSI, reflux symptom index.

      p-values are calculated using the paired t-test.

      Table 3. Changes in mean scores of each question based in GERD-HRQL questionnaire before TIF procedure and after 6 months of treatment

      GERD-HRQL, gastroesophageal reflux disease health-related quality of life; TIF, transoral incisionless fundoplication.

      Table 4. Changes in mean scores of each question based in RSI questionnaire before TIF procedure and after 6 months of treatment

      RSI, reflux symptom index; TIF, transoral incisionless fundoplication.


      Clin Endosc : Clinical Endoscopy Twitter Facebook
      Close layer
      TOP